Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.
Fang-Chi HsuYun YenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
A recent study evaluated the efficacy of pembrolizumab across various cancers, classified according to tumor mutational load (TML) defined by whole-genome sequencing. Tumors exhibiting intermediate to high TML showed improved clinical benefit from pembrolizumab. This proof-of-concept study highlights clinical value of TML in patient selection, advancing precision immunotherapy and treatment strategies. See related article by Geurts et al., p. 3735.